Learning Objectives: .


21 views
Uploaded on:
Description
Clinical Scenario. Human Papilloma Virus (HPV) Vaccination 23 year old female with abnormal pap test Written by: Martin C. Mahoney, MD, PhD, FAAFP, FACE Associate Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Transcripts
Slide 1

Clinical Scenario Human Papilloma Virus (HPV) Vaccination 23 year old female with strange pap test Written by: Martin C. Mahoney, MD, PhD, FAAFP, FACE Associate Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY Associate Professor, Department of Family Medicine, School of Medicine & Biomedical Sciences, SUNY at Buffalo, Buffalo, NY Associate Professor, School of Public Health and Health Professions, SUNY at Buffalo, Buffalo, NY Copyright 2007 Society of Teachers of Family Medicine Funded by an unlimited instructive allow from Merck & Co., Inc to STFM Foundation

Slide 2

Learning Objectives: survey the administration of strange pap smears portray utilization of the preventive HPV immunization among youthful grown-up ladies comprehend the justification for utilization of the preventive HPV antibody

Slide 3

The Scenario: Beth, a 23 year old lady, presents for a subsequent pap spread and refill of her OCP. Before an "unusual" pap 7 months prior, yearly pap spreads in the course of the most recent 3 years have been "typical." around then she was told to return around 6 months for another pap test.

Slide 4

The Scenario (cont) Beth denies dysuria or release at today\'s visit. Menstrual cycles are customary with direct stream. She is not in the blink of an eye sexually dynamic, but rather reports a sum of 5 sexual accomplices previously. She smokes 10 - 12 cigarettes every day. She is nulliparous.

Slide 5

The Scenario (cont): Review of her medicinal graph demonstrates pap spread cytology comes about because of 7 months back - atypical squamous cells of undetermined importance (ASC-US); reflex testing for Human Papilloma Virus (HPV) was sure for the nearness of high-hazard HPV. Colposcopy was negative. You start a discussion to investigate Beth\'s comprehension of HPV and clinical results. Beth reviews some of her lady friends specifying something about HPV in the past however her general information about HPV appears to be restricted. You prescribe that Beth get the HPV immunization arrangement with the main dosage to be given today.

Slide 6

Question 1: What is the ideal administration of ladies with ACS-US comes about on pap spread screening?

Slide 7

Answer 1: The 2001 agreement rules (Wright, Cox et al. 2002) portray three alternatives for dealing with an ACS-US pap result: 1) rehash cervical cytology at 4-6 months, or 2) DNA testing for high-chance sorts of HPV, or 3) colposcopy. The rules note testing for high hazard HPV DNA as the favored approach. Ladies who test positive for high hazard HPV DNA ought to finish colposcopy. In the event that high hazard HPV DNA is not identified, cytology testing ought to be rehashed in 1 year. (Just the high hazard HPV test board ought to be requested, since the nearness of generally safe HPV DNA has no effect on clinical administration.)

Slide 8

For Beth\'s situation, reflex HPV DNA testing was sure for the nearness of high hazard HPV sorts. Colposcopy was negative and rehash cytologic testing at 6 months & 12 months was prescribed. In the event that both the 6 & 12 month pap spread outcomes are negative, yearly screening can be continued.

Slide 9

Question 2: How normal are HPV contaminations?

Slide 10

Answer 2: Prevalent HPV contaminations in the United States surpass 20 million, while upwards of 5.5 million cases new HPV diseases are obtained yearly. (Cates 1999) 75% of sexually dynamic men and ladies have been presented to HPV eventually in their lives. (Koutsky, Galloway et al. 1988) Males and females have all the earmarks of being similarly influenced. HPV commonness among juvenile young ladies and youthful grown-up ladies run from 28%-82%, (Burk, Ho et al. 1996; Brown, Shew et al. 2005) while predominance rates among pre-adult and youthful grown-up guys extend between 29%-48%. (Kataoka, Claesson et al. 1991; Svare, Kjaer et al. 2002)

Slide 12

Question 3: How is HPV transmitted?

Slide 13

Answer 3: Insertive intercourse speaks to the most effective strategy for contamination, in spite of the fact that HPV can be transmitted however any skin-to-skin contact. Inside ~36 months of first intercourse, the aggregate occurrence of HPV disease among female understudies who were HPV negative at time of enlistment achieved half. (Winer, Lee et al. 2003) Consistent utilization of condoms can diminish the danger of sexually transmitted diseases and pregancy, however are not generally powerful in avoiding HPV contamination. You stress to both Abigail and her mom that a judicious hazard lessening procedure ought to incorporate the ABCs: Abstinence, Be steadfast, Condom utilize.

Slide 14

Question 4: What sickness results are connected with HPV disease?

Slide 15

Answer 4: The 40 sorts of HPV infections which contaminate epithelial tissues incorporate both "high-hazard" and "generally safe" sorts based upon the kind of sickness results coming about because of disease. High-hazard HPV diseases (e.g., HPV-16, - 18, - 31, - 33, etcetera) show as pap spread irregularities – second rate interepithelial sores (LSIL), high review interepithelial sores (HSIL), cervical tumors and different malignancies of the anogenital district. (Cox 1995; Munoz, Bosch et al. 2003) Infection with generally safe HPV sorts (e.g., HPV-6, - 11, etcetera) show as poor quality pap spread variations from the norm, genital warts, and intermittent respiratory papillomatosis (RRP), where obstructive papillomas shape on the larynx and vocal lines.

Slide 18

Question 5: What is the viability of HPV preventive antibodies?

Slide 19

Answer 5: Clinical trials of the quadrivalent HPV immunization (Gardasil®, Merck & Co., Inc., Whitehouse Station, NJ), which ensures against HPV-16, - 18, - 6, and - 11, and from clinical trials of a bivalent HPV antibody (Cervarix™, GlaxoSmithKline, London, UK), which secures against HPV 16 and 18, indicate adequacy inside the scope of 90% to 100% crosswise over reviews and clinical results. Gardasil® was FDA-endorsed in June 2006 while an application for Cervarix™ was submitted in March 2007.

Slide 20

Background on HPV Vaccines These antibodies depend on infection like particles (VLPs) got from the non-irresistible L1 external capsid proteins which initiate an immunologic reaction. (Fife, Wheeler et al. 2004) The antibodies are non-irresistible. Almost all members in clinical trials of HPV immunizations have shown seroconversion with counter acting agent levels a few overlap higher than those watched taking after regular contamination. (Harper, Franco et al. 2004; Sattler and Investigators. 2005; Skjeldestad and Committee 2005; Villa, Costa et al. 2005) Minimal immune response levels considered to give insurance against each of the HPV subtypes have not yet been set up. Besides, neutralizer levels are HPV type–specific and test particular, and it is impractical to analyze immune response levels crosswise over or inside trials.

Slide 21

Immunobridging Immunologic reactions to the quadrivalent HPV antibody among young men and young ladies, ages 9-15 years, are slightest practically identical to that saw among young ladies. (Nolan, Block et al. 2005; Reisinger, Block et al. 2006) These information can be utilized to "extension" adequacy information among young ladies incorporated into the viability trials finished to date, to other age bunches GMTs*

Slide 22

Immunobridging (cont) HPV4, quadrivalent HPV immunization, *GMT = Geometric mean titers for killing antibodies in light of aggressive Luminex immunoassay (cLIA); in mMU/mL (milli-Merck units); Block, et al., Pediatrics 2006.

Slide 23

Question 6: What is thought about the security of HPV preventive immunizations?

Slide 24

Answer 6: Consistent with different trials of antibodies, infusion site responses, for example, torment, swelling, and redness were basic among members in the HPV preventive immunization trials and were to some degree more continuous in the immunization amass. Torment seriousness was regularly reported as mellow to direct and for the most part went on for 1 to 2 days. Systemic side effects, for example, weakness, cerebral pain, rash, furious stomach, and temperature rise were equivalent between gatherings. The event of genuine unfriendly occasions was rare. Taken together, the information on unfavorable occasions from these trials recommend that the HPV preventive antibodies are all around endured. (Harper, Franco et al. 2004; Sattler and Investigators. 2005; Skjeldestad and Committee 2005; Villa, Costa et al. 2005; 2007; Ault 2007; Garland, Hernandez-Avila et al. 2007; Paavonen, Jenkins et al. 2007)

Slide 25

Question 7: What is the span of insurance?

Slide 26

Answer 7: At this point it is not known whether, or when, sponsor measurements for these HPV immunizations may be required. Follow-up information stretching out to around five years demonstrate proceeded with adequacy and immunogenicity for both the quadrivalent HPV antibody (Villa, Ault et al. 2006) and for the bivalent HPV immunization (Harper, Franco et al. 2006). Considers observing long haul adequacy stay in progress.

Slide 27

Question 8: Who ought to get the HPV preventive immunization?

Slide 28

Answer 8: The quadrivalent HPV antibody (Gardasil®, Merck) is endorsed for organization to young ladies and ladies ages 9 to 26 years as a 3 measurements arrangement. GlaxoSmithKline petitioned for FDA endorsement of Cervarix™ in March 2007.

Slide 29

Answer 8 (cont): Recommendations from the Advisory Committee on Immunization Practices (ACIP) incorporate routine utilization of the quadrivalent HPV antibody (HPV-6,- 11,- 16,- 18; Gardasil®) among young ladies at the 11-12 year visit; young ladies as youthful as age 9 years can be incorporated as a feature of an efficient way to deal with inoculation (Markowitz, Dunne et al. 2007).

Slide 30

Answer 8 (cont) The HPV preventive immunization ought to likewise be offered to all young ladies and ladies ages 13-26 years as a component of a get up to speed inoculation technique (Markowitz, Dunne et al. 2007). Preventive HPV antibodies will have adequacy among people who have not yet been presented to HPV.

Slide 31

What about utilization of HPV antibody in "uncommon circumstances"? The ACIP suggests utilization of the HPV antibody among ladies: -with a past filled with obscure/strange pap smears, -known to be HPV-positive to high hazard HPV DNA. - lactating, -immunocom

Recommended
View more...